[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100275317":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":13,"locations":21,"responsibleParty":37,"collaborators":7,"id":39,"slug":7,"hasResults":40,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":40,"sex":46,"minAge":47,"maxAge":7,"enrollmentInfo":48,"targetDuration":51,"studyType":52,"phases":7,"briefSummary":53,"conditions":54,"keywords":63,"overallStatus":24,"whyStopped":7,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"German CLL Study Group","OTHER",null,[9],{"name":10,"affiliation":11,"role":12},"Michael Hallek, MD","German CLL Study Group, Department I of Internal Medicine University Hospital Cologne","STUDY_DIRECTOR",[14,19],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Anna-Maria Fink, MD","CONTACT","+4922147888220","cllstudie@uk-koeln.de",{"name":20,"role":16,"phone":17,"phoneExt":7,"email":18},"Central Study Office of the German CLL Study Group",[22],{"facility":23,"status":24,"city":25,"state":26,"zip":7,"country":27,"cosmosGeoPoint":28,"geoPoint":33,"contacts":34},"BAG Freiberg-Richter, Jacobasch, Wolf, Illmer","RECRUITING","Dresden","Saxony","Germany",{"type":29,"coordinates":30},"Point",[31,32],13.73832,51.05089,{"lat":32,"lon":31},[35],{"name":36,"role":16,"phone":7,"phoneExt":7,"email":7},"Lutz Jakobasch, MD",{"type":38,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100275317",false,"NCT02863692","Registry of the German CLL Study Group","Registry of the German CLL Study Group Long Term Follow-up of Patients With CLL, B-PLL, T-PLL, SLL,T or NK-LGL, HCL and Richter's Transformation","CLL-Registry","Inclusion Criteria (all must apply)\n\n1. Confirmed diagnosis of CLL, B-PLL, T-PLL, SLL, T or NK-LGL, HCL or Richter's transformation\n2. 18 years of age or older\n3. Signed, written informed consent\n4. Presence of one or more of the following disease situations:\n\n   * Newly diagnosed patients without treatment indication (eligible for watch and wait Approach Treatment within a clinical trial according to the AMG or status post participation in a clinical Trial)\n   * Treatment with standard therapies approved for the eligible entities or status post treatment (outside of clinical trials)\n   * Referral for evaluation the indication for HSCT\n   * Relapsed disease status (even if first diagnosis was prior to activation of the registry)\n\nExclusion Criteria\n\n1. Patients without confirmed diagnosis of CLL, B-PLL, T-PLL, SLL, T or NK- LGL, HCL or Richter's transformation\n2. Cerebral dysfunction, legal incapacity","ALL","18 Years",{"count":49,"type":50},8000,"ESTIMATED","25 Years","OBSERVATIONAL","Long term follow-up of patients with chronic lymphocytic leukemia (CLL), B-prolymphocytic leukemia (B-PLL), T-cell prolymphocytic leukemia (T-PLL), Small lymphocytic lymphoma (SLL), T\u002FNatural Killer large granular lymphocyte leukemia (T or NK-LGL), Hairy cell leukemia (HCL) and Richter's transformation",[55,56,57,58,59,60,61,62],"CLL","SLL","HCL","Richter´s Transformation","Leukemia, Prolymphocytic, B-Cell","Leukemia, Prolymphocytic, T-Cell","T-LGL Leukemia","NK-LGL Leukemia",[55,64,65,56,66,57,58],"B-PLL","T-PLL","T-NK-LGL","2025-12-01",{"date":69,"type":70},"2025-12-08","ACTUAL",{"date":72,"type":7},"2013-08",{"date":74,"type":50},"2026-12",{"name":5,"class":6},1]